IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma

Hussein Tawbi, MD, PhD, emphasizes that combination immunotherapies offer higher efficacy than single agent PD-1 inhibitors for metastatic melanoma; however, patient characteristics guide the choice of treatment regimen, with toxicities playing a key role.